Abcellera Biologics INC Form 4 insider transactions

Thermopylae Holdings Ltd., a 10% owner of AbCellera Biologics Inc., reported a charitable donation of 286,000 common shares.

AbCellera Biologics CEO, Carl L.G. Hansen, exercised stock options and acquired 56,125 common shares at $2.70 per share on November 25, 2024.

Carl Hansen, CEO of AbCellera Biologics, reports the acquisition and disposal of common shares and the exercise of share options.

Thermopylae Holdings Ltd., a 10% owner of AbCellera Biologics Inc., acquired 283,516 common shares at an average price of $2.61 on August 29, 2024, increasing its direct holdings.

Veronique Lecault, COO of AbCellera Biologics, exercised stock options to acquire 83,334 common shares at $0.188 per share.

Director Michael R. Hayden reports acquisition of AbCellera Biologics shares through option exercise.

Director Andrew Lo reports acquisition of AbCellera Biologics shares through the exercise of share options.

Director John S. Montalbano reports acquisition of 163,934 shares of AbCellera Biologics through option exercise.

CEO Carl Hansen exercised stock options and sold a portion of the acquired shares, while also reporting indirect ownership through Thermopylae Holdings Ltd.

AbCellera Biologics CEO Carl L. G. Hansen exercised stock options and disposed of 56,125 common shares on February 26, 2024.